EAU24 Expert Commentary丨Professor Tongyi Men: Bringing More Hope to Kidney Cancer Patients Through the Latest Research Advances

EAU24 Expert Commentary丨Professor Tongyi Men: Bringing More Hope to Kidney Cancer Patients Through the Latest Research Advances

The situation of urological tumors in China is not optimistic, with the incidence of kidney cancer increasing annually by 4% to 7%. There is an urgent need to explore new diagnostic and therapeutic strategies to improve incidence rates and patient prognosis. The 39th Annual Congress of the European Association of Urology (EAU24) was held from April 5 to 8, 2024, in Paris, France. Oncology Frontier invited Professor Tongyi Men from the Affiliated Hospital of Inner Mongolia Medical University to share his insights from the conference and advancements in kidney cancer research.
2024 South-North Forum | Prof. Zhiming Shao: Breast Cancer Treatment in the Era of Precision Typing

2024 South-North Forum | Prof. Zhiming Shao: Breast Cancer Treatment in the Era of Precision Typing

Breast diseases have the highest incidence among women, with breast cancer being the leading malignant tumor threatening women's health. From "one-size-fits-all" treatments to "individualized therapy" based on patients, the exploration of breast cancer treatment has been ongoing for centuries. At the 2024 South-North Forum, Prof. Zhiming Shao from Fudan University Cancer Hospital presented a report titled "Precision Typing Drives Diagnosis and Treatment Innovation: A New Model for Breast Cancer Precision Diagnosis and Treatment." This article introduces the key points of the report.

Multiparametric MRI Differentiates Small Hepatocellular Carcinoma (<3 cm) from Benign Liver Lesions Associated with Budd-Chiari Syndrome

The “International Liver Disease - Hepatic Vascular Disease Column” is an academic column initiated by Dr. Xingshun Qi from the Department of Gastroenterology at General Hospital of Northern Theater Command, in collaboration with the editorial team of International Liver Disease. This column regularly collects and organizes research progress in the field of hepatic vascular diseases, selecting an important literature piece for detailed discussion every two weeks (Wednesday). The aim is to help readers understand the underlying mechanisms, inspire clinical research thinking, and apply knowledge effectively.
High Frequency of Type 3 Dendritic Cells in CD1c+DCs on Day 28 Post-Allo-HSCT as a Potential Marker for Severe GVHD in Pediatric Patients

High Frequency of Type 3 Dendritic Cells in CD1c+DCs on Day 28 Post-Allo-HSCT as a Potential Marker for Severe GVHD in Pediatric Patients

llogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Chimeric Antigen Receptor T-cell (CAR-T) therapy have become crucial in the treatment of leukemia. However, the effectiveness and safety of these treatments continue to be hot topics of research. Recent breakthrough studies have provided valuable insights, particularly in the treatment of children with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), prevention and monitoring of graft-versus-host disease (GVHD), and management of complications following CAR-T therapy. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting, held from April 14 to 17, 2024, in Glasgow, UK, focused on the latest advancements in stem cell transplantation and cellular therapy, pushing forward better clinical outcomes for hematologic patients. At this conference, Professor Shaoyan Hu and her team from the Affiliated Children's Hospital of Soochow University reported on six studies. Oncology Frontier - Hematology Frontier specially invited Professor Shaoyan Hu and her team members to share their research findings on the efficacy and safety of allo-HSCT and CAR-T cell therapy in pediatric leukemia patients in a roundtable discussion format and to provide insightful commentary on these six studies.
2024 CSCO Guidelines Conference | Prof. Yao Zhu: Combining the Latest Research to Guide Prostate Cancer Treatment Guidelines for Patient Protection

2024 CSCO Guidelines Conference | Prof. Yao Zhu: Combining the Latest Research to Guide Prostate Cancer Treatment Guidelines for Patient Protection

Prostate cancer is a malignant tumor occurring in the male reproductive system. Although the incidence in China is lower than in Western countries, it has rapidly increased in recent years, now ranking as the sixth most common male malignancy. With rapid advances in related research, updating prostate cancer treatment guidelines based on the latest evidence-based medicine to suit China's specific context is crucial for early diagnosis, treatment, and improving prognosis. The 2024 CSCO Guidelines Conference is about to take place. "Oncology Frontier" invited Prof. Yao Zhu from Fudan University Cancer Hospital to share key points of the guideline updates.
2024 South-North Forum | Prof. Xiaowei Qi: Advancements in Dual Target Neoadjuvant Therapy for HER2-Positive Breast Cancer

2024 South-North Forum | Prof. Xiaowei Qi: Advancements in Dual Target Neoadjuvant Therapy for HER2-Positive Breast Cancer

In the first-line treatment of advanced HER2-positive breast cancer, the combination of pyrotinib and trastuzumab has introduced a new therapeutic model. The complementary mechanisms of large and small molecules have achieved a median progression-free survival (mPFS) of 24.3 months, setting a new standard for first-line treatment of advanced HER2-positive breast cancer. This combination therapy is now recommended by three major domestic guidelines: CSCO BC, CBCS, and ABCC. While the success of this dual-target regimen in advanced stages is clear, its effectiveness in early-stage treatment remains to be seen. Can it provide a new dual-target option for neoadjuvant therapy in HER2-positive breast cancer? In this issue, "Oncology Frontier" invites Prof. Xiaowei Qi to share insights from his report at the South-North Forum titled "Clinical and Translational Research on Pyrotinib Combined with Trastuzumab as Neoadjuvant Therapy for HER2-Positive Breast Cancer," offering an in-depth exploration of this new dual-target regimen in early anti-HER2 therapy.
EBMT Roundtable Discussion | Professor Shaoyan Hu’s Team: Efficacy and Safety of Allo-HSCT and CAR-T Cell Therapy in Pediatric Leukemia Patients

EBMT Roundtable Discussion | Professor Shaoyan Hu’s Team: Efficacy and Safety of Allo-HSCT and CAR-T Cell Therapy in Pediatric Leukemia Patients

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Chimeric Antigen Receptor T-cell (CAR-T) therapy have become crucial in the treatment of leukemia. However, the effectiveness and safety of these treatments continue to be hot topics of research. Recent breakthrough studies have provided valuable insights, particularly in the treatment of children with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), prevention and monitoring of graft-versus-host disease (GVHD), and management of complications following CAR-T therapy. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting, held from April 14 to 17, 2024, in Glasgow, UK, focused on the latest advancements in stem cell transplantation and cellular therapy, pushing forward better clinical outcomes for hematologic patients. At this conference, Professor Shaoyan Hu and her team from the Affiliated Children's Hospital of Soochow University reported on six studies. Oncology Frontier - Hematology Frontier specially invited Professor Shaoyan Hu and her team members to share their research findings on the efficacy and safety of allo-HSCT and CAR-T cell therapy in pediatric leukemia patients in a roundtable discussion format and to provide insightful commentary on these six studies.
Expert Perspective|Professor Jinjun Chen on Non-Invasive Diagnosis of Portal Hypertension in Patients with Advanced Chronic Liver Disease

Expert Perspective|Professor Jinjun Chen on Non-Invasive Diagnosis of Portal Hypertension in Patients with Advanced Chronic Liver Disease

Complications related to portal hypertension are the main cause of death in patients with advanced chronic liver disease (ACLD). Even after the underlying cause is controlled, clinical events during the progression of portal hypertension, such as esophageal variceal bleeding, ascites, overt hepatic encephalopathy, and acute-on-chronic liver failure, are the most critical factors leading to high mortality in chronic liver disease. The hepatic venous pressure gradient is the "gold standard" for assessing portal hypertension, and upper gastrointestinal endoscopy is an essential tool for screening and evaluating esophagogastric varices and their severity. However, both are invasive procedures, making them unsuitable for screening and monitoring portal hypertension. Non-invasive diagnostic methods based on spleen stiffness measurement (SSM) using vibration-controlled transient elastography can be used for screening, stratifying diagnosis, and monitoring portal hypertension and esophageal varices. At the recent 2024 Jinling Liver Disease Conference, Professor Jinjun Chen from Nanfang Hospital, shared advances in the non-invasive diagnosis of portal hypertension and esophagogastric varices in ACLD patients using spleen stiffness. The content is summarized as follows for the readers.
“CARTITUDE-2 Phase II Update: Cilta-cel for Multiple Myeloma Post 1-3 Prior Therapies or Early Relapse”

“CARTITUDE-2 Phase II Update: Cilta-cel for Multiple Myeloma Post 1-3 Prior Therapies or Early Relapse”

From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting was grandly held in Glasgow, UK, a city renowned for its historical significance. This year marks the 50th anniversary of EBMT, and the event gathered leading figures in the field of hematopoietic stem cell transplantation and over 6,000 hematology experts from around the world. The attendees reviewed the remarkable achievements in the fields of hematology and bone marrow transplantation over the past 50 years and explored forward-looking patient management strategies. At the conference, chimeric antigen receptor T-cell (CAR-T) therapy, a highlight of this meeting, showcased a series of breakthroughs in the treatment of multiple myeloma and lymphoma, attracting significant attention. This issue features a special invitation to Professor Jun Ma from the Harbin Institute of Hematological Oncology to provide an insightful interpretation of five major research studies in the field of CAR-T cell therapy. Here, we present a compilation of these insights for our readers.
EAU24 On-Site Highlights | Dr. Zedan Zhang of Professor Kan Gong’s Team on Perioperative Immunotherapy Strategies for MIBC

EAU24 On-Site Highlights | Dr. Zedan Zhang of Professor Kan Gong’s Team on Perioperative Immunotherapy Strategies for MIBC

Radical cystectomy (RC) and pelvic lymph node dissection (PLND) are standard treatments for muscle-invasive bladder cancer (MIBC), yet distant metastasis remains a challenge for some patients. Exploring perioperative treatment options for MIBC is crucial to improve patient outcomes. At the 39th Annual European Association of Urology (EAU24) Congress in Paris, France, "Oncology Frontier" invited Dr. Zedan Zhang from Professor Kan Gong’s team at Peking University First Hospital to discuss the latest advancements in MIBC perioperative treatment.